What is Leerink Partnrs' Forecast for SPRB FY2025 Earnings?

Key Points

• Leerink Partners revised down their FY2025 earnings estimate for Spruce Biosciences, projecting a loss of ($2.96) per share, down from a previous estimate of ($2.83).
• The consensus estimate for Spruce Biosciences' full-year earnings is a loss of ($1.00) per share, indicating a significant deviation from analyst predictions.
• Spruce Biosciences' stock has exhibited high volatility, with a 52-week low of $4.28 and a high of $240.00, currently trading near $129.92.

Spruce Biosciences, Inc. (NASDAQ:SPRB - Free Report) - Analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for shares of Spruce Biosciences in a research note issued on Tuesday, October 21st. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of ($2.96) per share for the year, down from their prior estimate of ($2.83). The consensus estimate for Spruce Biosciences' current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for Spruce Biosciences' Q4 2025 earnings at ($6.85) EPS, Q1 2026 earnings at ($7.13) EPS, Q2 2026 earnings at ($7.43) EPS, Q3 2026 earnings at ($7.75) EPS, Q4 2026 earnings at ($8.07) EPS, FY2026 earnings at ($30.38) EPS and FY2027 earnings at ($38.56) EPS.

A number of other brokerages have also recently issued reports on SPRB. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Spruce Biosciences in a report on Tuesday, October 14th. Leerink Partners set a $160.00 target price on Spruce Biosciences and gave the stock a "market perform" rating in a report on Tuesday. Finally, Zacks Research raised Spruce Biosciences from a "hold" rating to a "strong-buy" rating in a report on Thursday, October 16th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Spruce Biosciences presently has a consensus rating of "Hold" and a consensus price target of $140.83.

Spruce Biosciences Stock Performance

Spruce Biosciences stock opened at $129.92 on Friday. Spruce Biosciences has a 52 week low of $4.28 and a 52 week high of $240.00. The stock has a fifty day moving average of $49.79 and a 200-day moving average of $22.59. The stock has a market capitalization of $72.76 million, a P/E ratio of -1.51 and a beta of 2.47.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.